Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer

Hanan Goldberg, Abu Hijlih Ramiz, Rachel Glicksman, Noelia S. Salgado, Thenappan Chandrasekar, Zachary W A Klaassen, Christopher J.D. Wallis, Ali Hosni, Fabio Ynoe Moraes, Sangeet Ghai, Girish S. Kulkarni, Robert J. Hamilton, Nathan Perlis, Ants Toi, Peter Chung, Andrew Evans, Theo van der Kwast, Antonio Finelli, Neil Fleshner, Alejandro Berlin

Research output: Contribution to journalArticle

Abstract

Background: Extraprostatic extension (EPE) is defined as local spread of prostate cancer (PC) beyond prostate boundaries. Although extensively evaluated in radical prostatectomy (RP) specimens, its significance in prostate biopsy (PB) specimens is understudied. Objective: To analyze the clinicopathologic characteristics and treatment outcomes for patients with nonmetastatic PC with EPE on diagnostic PB. Design, setting, and participants: We identified all patients at Princess Margaret Cancer Center with EPE on their diagnostic PB between 2005 and 2016. All patients underwent definitive curative-intent treatment with either RP or radiotherapy (RT) with or without androgen deprivation therapy (ADT). Outcome measurements and statistical analyses: Clinicopathologic variables were compared using a χ2 or Kruskal-Wallis test; log-rank analyses were applied for outcomes comparison. Primary and secondary endpoints were 5-yr biochemical recurrence (BCR) and the occurrence of metastasis or cancer-specific death, respectively. Results and limitations: A total of 127 patients with reported EPE in their PB were identified. One-third of patients underwent RP (n = 43) and two-thirds received RT (n = 84). Baseline prognostic variables (prostate-specific antigen, clinical T stage, biopsy pathologic grade group, and proportion of cores involved with PC) were similar between the treatment groups. More than two-thirds of RT patients received concomitant ADT (median duration 36 mo, interquartile range 24–36), while 39.5% of RP patients received postoperative radiotherapy ± ADT. Of the RP patients, 95.3% had ≥pT3a disease and 27.9% had pN1 disease. Median follow-up after RP and RT was similar (43.7 vs 45.8 mo; p = 0.516). The 5-yr BCR and metastasis rates in the RP versus RT groups were 25.6% versus 11.9% (p = 0.09) and 7% versus 11.9% (p = 0.386), respectively. Only one patient died from metastatic PC (RT group). Limitations include the single-center and retrospective design with a moderate sample size and relatively short follow-up. Conclusions: EPE on PB is an infrequent finding that is strongly associated with high-risk clinicopathologic prognostic features that accurately predict EPE in RP specimens. Despite entailing aggressive disease characteristics, EPE on PB should not preclude patients from receiving definitive radical local therapy. Patient summary: Extraprostatic extension on prostate biopsies is an uncommon finding, but is strongly correlated to additional aggressive disease features. This finding accurately predicts the presence of extraprostatic extension on the final prostate specimen after surgery. Despite the associated high-risk features, finding extraprostatic extension in prostate biopsies should not preclude patients from undergoing curative-intent radical local therapy. Extraprostatic extension (EPE) on prostate biopsy is correlated with high-risk prostate cancer features, and predicts EPE on the final specimen. Despite its association with high = risk features, this finding should not preclude patients from receiving definitive local treatment.

Original languageEnglish (US)
Pages (from-to)88-96
Number of pages9
JournalEuropean Urology Oncology
Volume2
Issue number1
DOIs
StatePublished - Feb 1 2019

Fingerprint

Prostatic Neoplasms
Prostate
Biopsy
Prostatectomy
Radiotherapy
Androgens
Therapeutics
Neoplasm Metastasis
Recurrence
Prostate-Specific Antigen
Sample Size
Neoplasms

Keywords

  • Biochemical recurrence
  • Extraprostatic extension
  • Needle core biopsy
  • Prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Surgery
  • Oncology
  • Urology

Cite this

Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. / Goldberg, Hanan; Ramiz, Abu Hijlih; Glicksman, Rachel; Salgado, Noelia S.; Chandrasekar, Thenappan; Klaassen, Zachary W A; Wallis, Christopher J.D.; Hosni, Ali; Moraes, Fabio Ynoe; Ghai, Sangeet; Kulkarni, Girish S.; Hamilton, Robert J.; Perlis, Nathan; Toi, Ants; Chung, Peter; Evans, Andrew; van der Kwast, Theo; Finelli, Antonio; Fleshner, Neil; Berlin, Alejandro.

In: European Urology Oncology, Vol. 2, No. 1, 01.02.2019, p. 88-96.

Research output: Contribution to journalArticle

Goldberg, H, Ramiz, AH, Glicksman, R, Salgado, NS, Chandrasekar, T, Klaassen, ZWA, Wallis, CJD, Hosni, A, Moraes, FY, Ghai, S, Kulkarni, GS, Hamilton, RJ, Perlis, N, Toi, A, Chung, P, Evans, A, van der Kwast, T, Finelli, A, Fleshner, N & Berlin, A 2019, 'Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer', European Urology Oncology, vol. 2, no. 1, pp. 88-96. https://doi.org/10.1016/j.euo.2018.05.003
Goldberg, Hanan ; Ramiz, Abu Hijlih ; Glicksman, Rachel ; Salgado, Noelia S. ; Chandrasekar, Thenappan ; Klaassen, Zachary W A ; Wallis, Christopher J.D. ; Hosni, Ali ; Moraes, Fabio Ynoe ; Ghai, Sangeet ; Kulkarni, Girish S. ; Hamilton, Robert J. ; Perlis, Nathan ; Toi, Ants ; Chung, Peter ; Evans, Andrew ; van der Kwast, Theo ; Finelli, Antonio ; Fleshner, Neil ; Berlin, Alejandro. / Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. In: European Urology Oncology. 2019 ; Vol. 2, No. 1. pp. 88-96.
@article{7647c7038bd845da97d67f2bcbe92eb1,
title = "Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer",
abstract = "Background: Extraprostatic extension (EPE) is defined as local spread of prostate cancer (PC) beyond prostate boundaries. Although extensively evaluated in radical prostatectomy (RP) specimens, its significance in prostate biopsy (PB) specimens is understudied. Objective: To analyze the clinicopathologic characteristics and treatment outcomes for patients with nonmetastatic PC with EPE on diagnostic PB. Design, setting, and participants: We identified all patients at Princess Margaret Cancer Center with EPE on their diagnostic PB between 2005 and 2016. All patients underwent definitive curative-intent treatment with either RP or radiotherapy (RT) with or without androgen deprivation therapy (ADT). Outcome measurements and statistical analyses: Clinicopathologic variables were compared using a χ2 or Kruskal-Wallis test; log-rank analyses were applied for outcomes comparison. Primary and secondary endpoints were 5-yr biochemical recurrence (BCR) and the occurrence of metastasis or cancer-specific death, respectively. Results and limitations: A total of 127 patients with reported EPE in their PB were identified. One-third of patients underwent RP (n = 43) and two-thirds received RT (n = 84). Baseline prognostic variables (prostate-specific antigen, clinical T stage, biopsy pathologic grade group, and proportion of cores involved with PC) were similar between the treatment groups. More than two-thirds of RT patients received concomitant ADT (median duration 36 mo, interquartile range 24–36), while 39.5{\%} of RP patients received postoperative radiotherapy ± ADT. Of the RP patients, 95.3{\%} had ≥pT3a disease and 27.9{\%} had pN1 disease. Median follow-up after RP and RT was similar (43.7 vs 45.8 mo; p = 0.516). The 5-yr BCR and metastasis rates in the RP versus RT groups were 25.6{\%} versus 11.9{\%} (p = 0.09) and 7{\%} versus 11.9{\%} (p = 0.386), respectively. Only one patient died from metastatic PC (RT group). Limitations include the single-center and retrospective design with a moderate sample size and relatively short follow-up. Conclusions: EPE on PB is an infrequent finding that is strongly associated with high-risk clinicopathologic prognostic features that accurately predict EPE in RP specimens. Despite entailing aggressive disease characteristics, EPE on PB should not preclude patients from receiving definitive radical local therapy. Patient summary: Extraprostatic extension on prostate biopsies is an uncommon finding, but is strongly correlated to additional aggressive disease features. This finding accurately predicts the presence of extraprostatic extension on the final prostate specimen after surgery. Despite the associated high-risk features, finding extraprostatic extension in prostate biopsies should not preclude patients from undergoing curative-intent radical local therapy. Extraprostatic extension (EPE) on prostate biopsy is correlated with high-risk prostate cancer features, and predicts EPE on the final specimen. Despite its association with high = risk features, this finding should not preclude patients from receiving definitive local treatment.",
keywords = "Biochemical recurrence, Extraprostatic extension, Needle core biopsy, Prostate cancer",
author = "Hanan Goldberg and Ramiz, {Abu Hijlih} and Rachel Glicksman and Salgado, {Noelia S.} and Thenappan Chandrasekar and Klaassen, {Zachary W A} and Wallis, {Christopher J.D.} and Ali Hosni and Moraes, {Fabio Ynoe} and Sangeet Ghai and Kulkarni, {Girish S.} and Hamilton, {Robert J.} and Nathan Perlis and Ants Toi and Peter Chung and Andrew Evans and {van der Kwast}, Theo and Antonio Finelli and Neil Fleshner and Alejandro Berlin",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.euo.2018.05.003",
language = "English (US)",
volume = "2",
pages = "88--96",
journal = "European urology oncology",
issn = "2588-9311",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer

AU - Goldberg, Hanan

AU - Ramiz, Abu Hijlih

AU - Glicksman, Rachel

AU - Salgado, Noelia S.

AU - Chandrasekar, Thenappan

AU - Klaassen, Zachary W A

AU - Wallis, Christopher J.D.

AU - Hosni, Ali

AU - Moraes, Fabio Ynoe

AU - Ghai, Sangeet

AU - Kulkarni, Girish S.

AU - Hamilton, Robert J.

AU - Perlis, Nathan

AU - Toi, Ants

AU - Chung, Peter

AU - Evans, Andrew

AU - van der Kwast, Theo

AU - Finelli, Antonio

AU - Fleshner, Neil

AU - Berlin, Alejandro

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: Extraprostatic extension (EPE) is defined as local spread of prostate cancer (PC) beyond prostate boundaries. Although extensively evaluated in radical prostatectomy (RP) specimens, its significance in prostate biopsy (PB) specimens is understudied. Objective: To analyze the clinicopathologic characteristics and treatment outcomes for patients with nonmetastatic PC with EPE on diagnostic PB. Design, setting, and participants: We identified all patients at Princess Margaret Cancer Center with EPE on their diagnostic PB between 2005 and 2016. All patients underwent definitive curative-intent treatment with either RP or radiotherapy (RT) with or without androgen deprivation therapy (ADT). Outcome measurements and statistical analyses: Clinicopathologic variables were compared using a χ2 or Kruskal-Wallis test; log-rank analyses were applied for outcomes comparison. Primary and secondary endpoints were 5-yr biochemical recurrence (BCR) and the occurrence of metastasis or cancer-specific death, respectively. Results and limitations: A total of 127 patients with reported EPE in their PB were identified. One-third of patients underwent RP (n = 43) and two-thirds received RT (n = 84). Baseline prognostic variables (prostate-specific antigen, clinical T stage, biopsy pathologic grade group, and proportion of cores involved with PC) were similar between the treatment groups. More than two-thirds of RT patients received concomitant ADT (median duration 36 mo, interquartile range 24–36), while 39.5% of RP patients received postoperative radiotherapy ± ADT. Of the RP patients, 95.3% had ≥pT3a disease and 27.9% had pN1 disease. Median follow-up after RP and RT was similar (43.7 vs 45.8 mo; p = 0.516). The 5-yr BCR and metastasis rates in the RP versus RT groups were 25.6% versus 11.9% (p = 0.09) and 7% versus 11.9% (p = 0.386), respectively. Only one patient died from metastatic PC (RT group). Limitations include the single-center and retrospective design with a moderate sample size and relatively short follow-up. Conclusions: EPE on PB is an infrequent finding that is strongly associated with high-risk clinicopathologic prognostic features that accurately predict EPE in RP specimens. Despite entailing aggressive disease characteristics, EPE on PB should not preclude patients from receiving definitive radical local therapy. Patient summary: Extraprostatic extension on prostate biopsies is an uncommon finding, but is strongly correlated to additional aggressive disease features. This finding accurately predicts the presence of extraprostatic extension on the final prostate specimen after surgery. Despite the associated high-risk features, finding extraprostatic extension in prostate biopsies should not preclude patients from undergoing curative-intent radical local therapy. Extraprostatic extension (EPE) on prostate biopsy is correlated with high-risk prostate cancer features, and predicts EPE on the final specimen. Despite its association with high = risk features, this finding should not preclude patients from receiving definitive local treatment.

AB - Background: Extraprostatic extension (EPE) is defined as local spread of prostate cancer (PC) beyond prostate boundaries. Although extensively evaluated in radical prostatectomy (RP) specimens, its significance in prostate biopsy (PB) specimens is understudied. Objective: To analyze the clinicopathologic characteristics and treatment outcomes for patients with nonmetastatic PC with EPE on diagnostic PB. Design, setting, and participants: We identified all patients at Princess Margaret Cancer Center with EPE on their diagnostic PB between 2005 and 2016. All patients underwent definitive curative-intent treatment with either RP or radiotherapy (RT) with or without androgen deprivation therapy (ADT). Outcome measurements and statistical analyses: Clinicopathologic variables were compared using a χ2 or Kruskal-Wallis test; log-rank analyses were applied for outcomes comparison. Primary and secondary endpoints were 5-yr biochemical recurrence (BCR) and the occurrence of metastasis or cancer-specific death, respectively. Results and limitations: A total of 127 patients with reported EPE in their PB were identified. One-third of patients underwent RP (n = 43) and two-thirds received RT (n = 84). Baseline prognostic variables (prostate-specific antigen, clinical T stage, biopsy pathologic grade group, and proportion of cores involved with PC) were similar between the treatment groups. More than two-thirds of RT patients received concomitant ADT (median duration 36 mo, interquartile range 24–36), while 39.5% of RP patients received postoperative radiotherapy ± ADT. Of the RP patients, 95.3% had ≥pT3a disease and 27.9% had pN1 disease. Median follow-up after RP and RT was similar (43.7 vs 45.8 mo; p = 0.516). The 5-yr BCR and metastasis rates in the RP versus RT groups were 25.6% versus 11.9% (p = 0.09) and 7% versus 11.9% (p = 0.386), respectively. Only one patient died from metastatic PC (RT group). Limitations include the single-center and retrospective design with a moderate sample size and relatively short follow-up. Conclusions: EPE on PB is an infrequent finding that is strongly associated with high-risk clinicopathologic prognostic features that accurately predict EPE in RP specimens. Despite entailing aggressive disease characteristics, EPE on PB should not preclude patients from receiving definitive radical local therapy. Patient summary: Extraprostatic extension on prostate biopsies is an uncommon finding, but is strongly correlated to additional aggressive disease features. This finding accurately predicts the presence of extraprostatic extension on the final prostate specimen after surgery. Despite the associated high-risk features, finding extraprostatic extension in prostate biopsies should not preclude patients from undergoing curative-intent radical local therapy. Extraprostatic extension (EPE) on prostate biopsy is correlated with high-risk prostate cancer features, and predicts EPE on the final specimen. Despite its association with high = risk features, this finding should not preclude patients from receiving definitive local treatment.

KW - Biochemical recurrence

KW - Extraprostatic extension

KW - Needle core biopsy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85062800766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062800766&partnerID=8YFLogxK

U2 - 10.1016/j.euo.2018.05.003

DO - 10.1016/j.euo.2018.05.003

M3 - Article

VL - 2

SP - 88

EP - 96

JO - European urology oncology

JF - European urology oncology

SN - 2588-9311

IS - 1

ER -